When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Frozen’s Josh Gad shared insight into his weight loss journey after losing 40 pounds with the help of medication.

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.